USFDA granted approval to Aurobindo Pharma for Flucytosine Capsules

Aurobindo Pharma received its final approval from the US Food & Drug Administration (USFDA) to manufacture and market Flucytosine Capsules, 250 mg and 500 mg.

Flucytosine Capsules are used for the treatment of serious infections caused by susceptible strains of Candida and Cryptococcus. The Capsules are a generic version of Bausch Health’s Ancobon Capsules and the capsules will be launched in June 2020.

A total of 429 ANDA approvals has been granted to Aurobindo (401 Final approvals including 23 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.

  • Related Posts

    Government Launches Incentive Scheme for Medical Device Manufacturers

    In a major push to strengthen India’s medical device ecosystem, the Ministry of Chemicals and Fertilisers has invited applications from eligible companies under the Scheme for Strengthening of Medical Device…

    Which drug works best for you? One blood test can tell

    Ever wondered why a medicine works perfectly for one person while having no effect on the other? For instance, folic acid is usually prescribed to someone with high levels of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Government Launches Incentive Scheme for Medical Device Manufacturers

    Government Launches Incentive Scheme for Medical Device Manufacturers

    Which drug works best for you? One blood test can tell

    Which drug works best for you? One blood test can tell

    Mirror exposé triggers plasma transfer overhaul

    Mirror exposé triggers plasma transfer overhaul

    Minister JP Nadda launches drug registry to standardise medicine-related information

    Minister JP Nadda launches drug registry to standardise medicine-related information

    Pharmexcil urges companies to adopt NCB voluntary code to prevent chemical diversion into illegal drug production

    Pharmexcil urges companies to adopt NCB voluntary code to prevent chemical diversion into illegal drug production

    Govt review finds no common thread in post-delivery deaths